Genascence’s $10.5 Million Series A Financing

Latham & Watkins advised Genascence in the transaction.Genascence Corporation (Genascence), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, has completed the…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Laura Testa

Author: Laura Testa

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here